Economics of the clinical management of lung cancer in France: an analysis using a Markov model.

摘要: To evaluate, according to the histologic type and initial stage, mean cost (MC) of managing patients with lung cancer costs different management phases. A Markov approach was used model these costs, based on a representative nation-wide sample 428 newly diagnosed cancer. The 18-month MC ranged from US$ 20 691 (95% CI: 5777–50 380 for diffuse non-small-cell (NSCLC) 31 833 15 866–64 455) localised smallcell (SCLC); first-line treatment 33.8% medically inoperable NSCLC 74.6% SCLC; second- or third-line 7.8% surgically treated 32% locally advanced NSCLC; palliative care 9.1% 39.9% NSCLC. chemotherapy percentage actively impacted more than did regimens care. In conclusion, this provides robust economic analysis management, will be useful assessing consequences future changes in patient management.